Compare Abeona Therapeutics Inc (ABEO) vs American Express Co (AXP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs American Express Co — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while American Express Co trades at $338.27 (market cap $238.53B). The key difference: American Express Co is far larger — about 638.9× Abeona Therapeutics Inc's market cap, and American Express Co pays a 1.09% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AXP | |
|---|---|---|
Market Cap | $373.32M | $238.53B |
Sector | Health | Financials |
52-Week High | $7.23 | $384.82 |
52-Week Low | $4.17 | $292.27 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AXP trades at $349.58, down 0.68% on the day, with a bullish technical outlook and strong fundamentals. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.13% margin. Recent earnings beat expectations in Q1 2026, and analyst consensus targets $376.36. The stock benefits from premium cardholder growth and strategic partnerships.
Outlook remains positive with mid-teens earnings growth potential, though risks include consumer spending sensitivity and competitive pressures. Institutional sentiment is mixed with 38.6% buy ratings. The current price near $350 offers upside to the consensus target, supported by operational cash flow strength and dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →
